Healthcare
Live Price
Offline$209.88
+1.76% today
1Y Change
+13.07%
Window
Jun 30, 2025 → Jun 24, 2026
Coverage: 247 bars · Jun 30, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Quest Diagnostics Incorporated (DGX) is a Healthcare stock with a market cap of $21.13B and listed on NYSE. The stock last traded around $209.88 and up 13.1% across the available one-year price window (Jun 30, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of +11.8%, EPS growth of +13.7%, a dividend yield of 1.7%. What stands out right now is revenue +11.8%, EPS +13.7%, free cash flow +49.5% with operating margin 14.3% and ROIC 8.1%. The dividend is present but secondary, with a yield around 1.7%. Valuation is more restrained than many high-expectation growth names at P/E 20.5 and price/sales 1.9. Stock Foundry combines DGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
DGX is 5.60 pts behind over the shared 1Y window.
DGX had 2.81 pts deeper max drawdown than SPY.
DGX beat SPY in 1 of 2 calendar years shown and trailed in 1.
DGX
+13.07%
Normalized return
SPY
+18.68%
S&P 500
Excess Return
-5.60 pts
Relative to SPY
DGX Max Drawdown
-11.94%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for DGX and SPY.
| Year | DGX | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +16.87% | +6.71% | +10.16 pts | DGX |
| 2025 | -2.30% | +11.19% | -13.50 pts | SPY |
Unable to load analyst forecasts.
Timed out loading forecasts for DGX
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.